Section Arrow
Quote
TNFA.NASDAQ
- TNF Pharmaceuticals Inc.
(Financial Status)
Quotes are at least 15-min delayed:2025/09/05 12:23 EDT
Regular Hours
Last
 3.3586
-0.2514 (-6.96%)
Day High 
3.59 
Prev. Close
3.61 
1-M High
12.24 
Volume 
206.17K 
Bid
3.34
Ask
3.36
Day Low
3.2811 
Open
3.5 
1-M Low
3.29 
Market Cap 
512.04K 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.93 
20-SMA 8.04 
50-SMA 10.19 
52-W High 195 
52-W Low 3.29 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-202.00/-0.00
Enterprise Value
512.04K
Balance Sheet
Book Value Per Share
0.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NUVBNuvation Bio3.98+0.56+16.37%-- 
ADAPAdaptimmune Therapeutics plc0.0491-0.0019-3.73%-- 
IOVAIovance Biotherapeutics2.435+0.235+10.68%-- 
RXRXRecursion Pharmaceuticals4.585+0.065+1.44%-- 
KLTOKlotho Neurosciences Inc0.4298-0.0652-13.17%-- 
Quotes are at least 15-min delayed：2025/09/05 12:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailtyand sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.